Enrollment Begins for Phase I Trial of NPI-0052 in Myeloma

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 6
Volume 16
Issue 6

NORWALK, Connecticut—The Multiple Myeloma Research Consortium (MMRC) and Nereus Pharmaceuticals, Inc., San Diego, have initiated enrollment in a multicenter phase I clinical trial to study Nereus' novel, second-generation proteasome inhibitor NPI-0052 in patients with relapsed or relapsed/refractory multiple myeloma. Participants in the open-label study will receive escalating, once-weekly intravenous doses of NPI-0052. The compound was discovered during the fermentation of a new marine actinomycete (Salinispora tropica).

NORWALK, Connecticut—The Multiple Myeloma Research Consortium (MMRC) and Nereus Pharmaceuticals, Inc., San Diego, have initiated enrollment in a multicenter phase I clinical trial to study Nereus' novel, second-generation proteasome inhibitor NPI-0052 in patients with relapsed or relapsed/refractory multiple myeloma. Participants in the open-label study will receive escalating, once-weekly intravenous doses of NPI-0052. The compound was discovered during the fermentation of a new marine actinomycete (Salinispora tropica).

Articles in this issue
ACS Launches Major Epidemiology Study
Pt Selection Key to Radioembolization of Liver Ca's
Million Dollar Gotham Prize Announced
Diagnostic Dilemma: GI Disease
Velcade/Doxil Approved for Relapsed or Refractory Multiple Myeloma Pts
Junovan Fails to Win ODAC Nod for Osteosarcoma Treatment
Surveillance Colonoscopy Guidelines Not Being Followed
Removing Stage IV Primary May Cut Mortality
Nuclear Export Inhibitors Testing Moving Forward
ODAC: orBec Yields No 'Substantial Efficacy' in GI GVHD
Gene Expression Profiles of HCC Revealed on CT Scans
Best Measure of Lung Cancer Screening: Curability or Mortality?
New Labeling Restrictions for ESAs: ODAC
Value-Based Competition Key to Healthcare Reform
Cranial Irradiation Prevents CNS Metastases in SCLC
Recent Videos
Combining daratumumab with other agents is one strategy that investigators are exploring in the smoldering multiple myeloma field.
A substantial portion of patients who received daratumumab in the AQUILA study were able to delay disease progression to active multiple myeloma.
The approval of daratumumab validates the notion of using limited therapy to help delay progression from smoldering disease to multiple myeloma.
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
Andrezj Jakubowiak, MD, PhD, prioritizes KRd-based regimens for the treatment of high-risk newly diagnosed disease in the post-transplant setting.
Although a similar proportion achieved MRD negativity at the 10 to the –6 power, not enough studies have analyzed MRD at this level for multiple myeloma.
Related Content
Early Response Rates Noted With Elranatamab/Iberdomide in R/R Multiple Myeloma

Early Response Rates Noted With Elranatamab/Iberdomide in R/R Multiple Myeloma

Kristi Rosa
December 6th 2025
Article

Results from the MagnetisMM-30 trial showed early ORR data with elranatamab/iberdomide in R/R multiple myeloma.

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Evolutions Across NSCLC, Multiple Myeloma, and AML at Georgia Cancer Center

Girindra Raval, MD;Amany Keruakous, MD;Daniel Peters, MD
December 1st 2025
Podcast

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

The 2.5 year progression-free survival rate was 80.5% with cilta-cel for this population, suggesting a potential cure fraction.

Cilta-Cel Exhibits Long-Term Survival in Standard-Risk R/R Multiple Myeloma

Chris Ryan
December 6th 2025
Article

The 2.5 year progression-free survival rate was 80.5% with cilta-cel for this population, suggesting a potential cure fraction.

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025
Podcast

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Real-World Elranatamab Maintains Responses in Elderly, Frail R/R Multiple Myeloma

Real-World Elranatamab Maintains Responses in Elderly, Frail R/R Multiple Myeloma

Tim Cortese
December 6th 2025
Article

Elevated LDH levels were associated with worse PFS and OS outcomes in patients with relapsed/refractory multiple myeloma treated with elranatamab.

Teclistamab shows promising real-world effectiveness for relapsed/refractory multiple myeloma, with high response rates and manageable safety profiles.

How Has Teclistamab Administration Translated Into Community MM Settings?

ONCOLOGY Staff
December 6th 2025
Article

Teclistamab shows promising real-world effectiveness for relapsed/refractory multiple myeloma, with high response rates and manageable safety profiles.